سعر ريفوليد 50مجم 14 قرص 2024
Revoladeمعلومات الدواء
التفاصيل الكاملةعن الدواءAbout the medicine
Eltrombopag 50 mg film-coated tablets (Revolade), oral thrombopoietin receptor agonist used for thrombocytopenia.
Eltrombopag 50 mg film-coated tablets (Revolade), oral thrombopoietin receptor agonist used for thrombocytopenia.
دواعي الاستعمالUses
- Primary immune thrombocytopenia (ITP) refractory to other treatments (e.g. corticosteroids, immunoglobulins).الفئة: AdultsEuropean Medicines Agency (EMA)
- Primary ITP lasting 6 months or longer from diagnosis and refractory to other treatments.الفئة: Children aged 1 year and aboveEuropean Medicines Agency (EMA)
- Thrombocytopenia in chronic hepatitis C where thrombocytopenia prevents initiation or limits optimal interferon-based therapy.الفئة: AdultsEuropean Medicines Agency (EMA)
- Primary immune thrombocytopenia (ITP) refractory to other treatments (e.g. corticosteroids, immunoglobulins).Population: AdultsEuropean Medicines Agency (EMA)
- Primary ITP lasting 6 months or longer from diagnosis and refractory to other treatments.Population: Children aged 1 year and aboveEuropean Medicines Agency (EMA)
- Thrombocytopenia in chronic hepatitis C where thrombocytopenia prevents initiation or limits optimal interferon-based therapy.Population: AdultsEuropean Medicines Agency (EMA)
الآثار الجانبيةSide effects
- In adult ITP the most important serious adverse reactions were hepatotoxicity and thrombotic/thromboembolic events; the most common (>= 10%) were nausea, diarrhoea, increased ALT and back pain.نشرة دولية لنفس المنتج · European Medicines Agency (EMA)
- In adult ITP the most important serious adverse reactions were hepatotoxicity and thrombotic/thromboembolic events; the most common (>= 10%) were nausea, diarrhoea, increased ALT and back pain.International label, same product · European Medicines Agency (EMA)
موانع الاستعمالContraindications
- Hypersensitivity to eltrombopag or any excipient.نشرة دولية لنفس المنتج · European Medicines Agency (EMA)
- Hypersensitivity to eltrombopag or any excipient.International label, same product · European Medicines Agency (EMA)
تحذيرات واحتياطاتWarnings & precautions
- Can cause abnormal liver function and severe, potentially life-threatening hepatotoxicity; measure ALT, AST and bilirubin before starting, every 2 weeks during dose adjustment and monthly once stable; discontinue for specified persistent/progressive ALT elevations.نشرة دولية لنفس المنتج · European Medicines Agency (EMA)
- Boxed warning: risk of hepatic decompensation in chronic hepatitis C patients when combined with interferon and ribavirin, and risk of hepatotoxicity.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Can cause abnormal liver function and severe, potentially life-threatening hepatotoxicity; measure ALT, AST and bilirubin before starting, every 2 weeks during dose adjustment and monthly once stable; discontinue for specified persistent/progressive ALT elevations.International label, same product · European Medicines Agency (EMA)
- Boxed warning: risk of hepatic decompensation in chronic hepatitis C patients when combined with interferon and ribavirin, and risk of hepatotoxicity.International label, same formulation · DailyMed (U.S. National Library of Medicine)
التداخلات الدوائيةDrug interactions
- Polyvalent cations (antacids, dairy products, mineral supplements with iron, calcium, magnesium, aluminium, selenium, zinc)Eltrombopag chelates polyvalent cations, markedly reducing its absorption; separate administration (at least 2 h before or 4 h after).European Medicines Agency (EMA)
- Rosuvastatin and other HMG-CoA reductase inhibitors (statins)Eltrombopag (OATP1B1/BCRP inhibition) increased rosuvastatin Cmax by 103%; consider reduced statin dose and monitor for statin adverse reactions.European Medicines Agency (EMA)
- Polyvalent cations (antacids, dairy products, mineral supplements with iron, calcium, magnesium, aluminium, selenium, zinc)Eltrombopag chelates polyvalent cations, markedly reducing its absorption; separate administration (at least 2 h before or 4 h after).European Medicines Agency (EMA)
- Rosuvastatin and other HMG-CoA reductase inhibitors (statins)Eltrombopag (OATP1B1/BCRP inhibition) increased rosuvastatin Cmax by 103%; consider reduced statin dose and monitor for statin adverse reactions.European Medicines Agency (EMA)
الحمل والرضاعةPregnancy & breastfeeding
- Limited human data; animal studies showed reproductive toxicity. Revolade is not recommended during pregnancy or in women of childbearing potential not using contraception.نشرة دولية لنفس المنتج · European Medicines Agency (EMA)
- Unknown whether excreted in human milk; animal data suggest secretion into milk, so a risk to the suckling child cannot be excluded; decide whether to discontinue breast-feeding or therapy.نشرة دولية لنفس المنتج · European Medicines Agency (EMA)
- Limited human data; animal studies showed reproductive toxicity. Revolade is not recommended during pregnancy or in women of childbearing potential not using contraception.International label, same product · European Medicines Agency (EMA)
- Unknown whether excreted in human milk; animal data suggest secretion into milk, so a risk to the suckling child cannot be excluded; decide whether to discontinue breast-feeding or therapy.International label, same product · European Medicines Agency (EMA)
كيف يعمل الدواءHow it works
- Small-molecule thrombopoietin receptor agonist that stimulates megakaryocyte proliferation and differentiation, increasing platelet production.
- Eltrombopag olamine: Small-molecule thrombopoietin receptor agonist that stimulates megakaryocyte proliferation and differentiation, increasing platelet production.
البدائل (3)
كل البدائل (3)مادة فعالة مختلفة من نفس المجموعة العلاجية. لا تستبدل دواءك ببديل إلا بأمر الطبيب.
| الدواء | السعر |
|---|---|
| ازيلينات 250 مجم 20 قرصEselinate 250mg 20 tab.Ravizza · أقراص · 250 mg | السعر2.1ج.م0.11ج.م للوحدة |
| ايتاسينون 250 مجم 20 قرصEtacynone 250 mgAlexandria · قرص · 250 mg | السعر13ج.م0.65ج.م للوحدة |
| هيموستاتين 500مجم 30 قرصHaemostatine 500mg 30 tabMulticare · قرص · 500 mg | السعر84ج.م2.8ج.م للوحدة |
تاريخ السعر
تغيّر السعر الرسمي: من 6,043 إلى 8,233 ج.م، 2 أسعار مسجلة
| التاريخ | السعر (ج.م) |
|---|---|
| سعر سابق بدون تاريخ | 6,043 |
| 8,233 |
| التاريخ | من | إلى | التغيير |
|---|---|---|---|
| 6,043ج.م | 8,233ج.م | زيادة 36.2% |
المعرّفات
- تصنيف ATC
- مراجع علمية للمادة الفعالة
- Eltrombopag olaminePubChem (يفتح في نافذة جديدة)
أدوية ذات صلة
نفس المادة الفعالة بتركيز آخر
منتجات أخرى من GlaxoSmithKline
- امبروكسول 30مجم 20 قرصأقراص5.5ج.م
- امبروكسول ممتد المفعول 75 10 كبسولةكبسولات صلبة ممتدة المفعول9.25ج.م
- انورو اليبيتا جهاز الاستنشاق 62.5 / 25ميكرو 30 جرعة مقننةمسحوق للاستنشاق معبأ مسبقاً (جهاز إليبتا)850ج.م
- اريكسترا 10 مجم /0.8 مل 10 سرنجات معبأة للحقن تحت الجلدمحلول للحقن في سرنجة معبأة مسبقاً1,050ج.م
- اريكسترا 5مجم /0.4مل حقن 10 سرنجات معبأة للحقن تحت الجلدمحلول للحقن في سرنجة معبأة مسبقاً980ج.م
- افاميس بخاخة سبراي للانفبخاخ أنفي (معلق)160ج.م
من نفس الفئة
المصادر
- السعر: قوائم أسعار الأدوية المنشورة في مصر.
- European Medicines Agency (EMA)
- DailyMed (U.S. National Library of Medicine)
- WHO Collaborating Centre for Drug Statistics Methodology
- PubChem (NCBI)
تعليقات
لا توجد تعليقات بعد. كن أول من يشارك تجربته مع هذا الدواء.
أضف تعليقًا